Chemomab Therapeutics (CMMB) Other Operating Expenses (2019 - 2020)
Chemomab Therapeutics (CMMB) posted Other Operating Expenses of $5.1 million for Q4 2020, up 6588.61% on a QoQ basis from -$79000.0 in Q3 2020, and up 53.01% year-over-year from $3.4 million in Q1 2020.
Chemomab Therapeutics (CMMB) Other Operating Expenses (2019 - 2020) Analysis & Trends
Chemomab Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at $5.1 million for Q4 2020.
- Quarterly Other Operating Expenses rose 53.01% year-over-year to $5.1 million in Q4 2020, while the trailing twelve-month figure through Sep 2021 was $5.1 million (up 97.08% YoY) and the FY2021 annual result came in at -$216000.0, down 104.93% from the prior year.
- Other Operating Expenses was $5.1 million for Q4 2020 at Chemomab Therapeutics, up from -$79000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $5.1 million in Q4 2020 and bottomed at -$670000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Chemomab Therapeutics | 704.11 Mn | 693.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 5.13 Mn |
| Sep 30, 2020 | -79,000.00 |
| Mar 31, 2020 | -670,000.00 |
| Dec 31, 2019 | 3.35 Mn |